SINOPHARM GROUP 1/5/O.N. (F:X2S1) — Market Cap & Net Worth
Market Cap & Net Worth: SINOPHARM GROUP 1/5/O.N. (X2S1)
SINOPHARM GROUP 1/5/O.N. (F:X2S1) has a market capitalization of $2.57 Billion (€2.20 Billion) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #5391 globally and #857 in its home market, demonstrating a -4.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SINOPHARM GROUP 1/5/O.N.'s stock price €8.20 by its total outstanding shares 268362148 (268.36 Million). Also see X2S1 asset base for a full breakdown of the balance sheet.
SINOPHARM GROUP 1/5/O.N. Market Cap History: 2021 to 2026
SINOPHARM GROUP 1/5/O.N.'s market capitalization history from 2021 to 2026. Data shows growth from $2.51 Billion to $2.57 Billion (0.18% CAGR). Also see SINOPHARM GROUP 1/5/O.N. (X2S1) cash conversion ratio for how efficiently the company converts equity into cash flow.
SINOPHARM GROUP 1/5/O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SINOPHARM GROUP 1/5/O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SINOPHARM GROUP 1/5/O.N. stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
SINOPHARM GROUP 1/5/O.N.'s market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.46x
SINOPHARM GROUP 1/5/O.N.'s market cap is 0.46 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.51 Billion | $521.05 Billion | $7.76 Billion | 0.00x | 0.32x |
| 2022 | $3.36 Billion | $552.15 Billion | $8.53 Billion | 0.01x | 0.39x |
| 2023 | $3.49 Billion | $596.57 Billion | $9.05 Billion | 0.01x | 0.39x |
| 2024 | $4.17 Billion | $584.51 Billion | $7.05 Billion | 0.01x | 0.59x |
| 2025 | $3.33 Billion | $575.17 Billion | $7.16 Billion | 0.01x | 0.46x |
Competitor Companies of X2S1 by Market Capitalization
Companies near SINOPHARM GROUP 1/5/O.N. in the global market cap rankings as of September 19, 2026. Review SINOPHARM GROUP 1/5/O.N. tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SINOPHARM GROUP 1/5/O.N. by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #249 globally with a market cap of $101.38 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #544 globally with a market cap of $50.53 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #645 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1240 globally with a market cap of $20.83 Billion USD ( AU$29.44 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #249 | McKesson Corporation | NYSE:MCK | $101.38 Billion | $874.65 |
| #544 | Cencora Inc. | NYSE:COR | $50.53 Billion | $308.78 |
| #645 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $225.38 |
| #1240 | Sigma Healthcare Ltd | AU:SIG | $20.83 Billion | AU$2.55 |
SINOPHARM GROUP 1/5/O.N. Historical Marketcap From 2021 to 2026
Between 2021 and today, SINOPHARM GROUP 1/5/O.N.'s market cap moved from $2.51 Billion to $ 2.57 Billion, with a yearly change of 0.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.57 Billion | -22.64% |
| 2025 | €3.33 Billion | -20.30% |
| 2024 | €4.17 Billion | +19.57% |
| 2023 | €3.49 Billion | +3.82% |
| 2022 | €3.36 Billion | +33.81% |
| 2021 | €2.51 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of SINOPHARM GROUP 1/5/O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.57 Billion USD |
| MoneyControl | $2.57 Billion USD |
| MarketWatch | $2.57 Billion USD |
| marketcap.company | $2.57 Billion USD |
| Reuters | $2.57 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SINOPHARM GROUP 1/5/O.N.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more